SCHEMBL27223707

SCHEMBL27223707

CC(=O)c1ccc(-c2ccsc2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ CHEK2 O96017 2/20 0.40
▸ HSD17B14 Q9BPX1 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ ERN1 O75460 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ NOX1 Q9Y5S8 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ S100A4 P26447 1/20 0.38
▸ TUBB4A P04350 1/20 0.38
▸ TUBB P07437 1/20 0.38
▸ TUBA3C P0DPH7 1/20 0.38
▸ TUBA1B P68363 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29713875 1.00 MAPT (0.41) MAPTNPC1RAB9ACHEK2HSD17B14
SCHEMBL27223736 0.84 KDM4E (0.46) MAPTERN1LMNAPTGS1TUBB4A
SCHEMBL27223846 0.82 BRD4 (0.45) NPC1RAB9ACHEK2HSD17B14ADORA3
SCHEMBL18458312 0.81 CHEK2 (0.46) MAPTNPC1RAB9ACHEK2ADORA3
SCHEMBL10269902 0.77 PTGS1 (0.55) MAPTNPC1RAB9ALMNAPTGS1
SCHEMBL18458311 0.77 MAPT (0.48) MAPTERN1MAPK1L3MBTL1ALDH1A1
SCHEMBL4450345 0.74 PDGFRB (0.47) ERN1LMNAALDH1A1
SCHEMBL6516791 0.74 HSD17B1 (0.55) MAPTNPC1RAB9ACHEK2ADORA3
SCHEMBL5305947 0.73 AKR1C3 (0.48) MAPTNPC1RAB9AHSD17B14PTGS1
SCHEMBL6313842 0.73 SYK (0.43) MAPTNPC1RAB9ACHEK2S100A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577245-B2 Sulfonyl benzamide derivatives as Bcl-2 inhibitors ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2026-03-17 — — US disclosed
US-20240166644-A1 SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS ASCENTAGE PHARMA GROUP CORP LIMITED (CN) 2024-05-23 — — US disclosed
CN-114835704-B Sulfonylbenzamide derivatives as BCL-2 inhibitors 苏州亚盛药业有限公司 2023-10-27 — — CN disclosed
CN-114835704-A Sulfonylbenzamide derivatives as BCL-2 inhibitors 苏州亚盛药业有限公司 2022-08-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577245-B2 Sulfonyl benzamide derivatives as Bcl-2 inhibitors BCL2A1, BCL2L1, BCL2L11 MAPT 4049/4885NPC1 517/4885RAB9A 1139/4885
US-20240166644-A1 SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 MAPT 1871/4885NPC1 1858/4885RAB9A 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback